Industry
Yuhan to market Samsung Bioepis’ Remicade, Enbrel biosimilars in Korea
Oct. 11, 2017
South Korean pharmaceutical company Yuhan Corp. said Wednesday that it had become Samsung Bioepis’ exclusive marketing partner to sell two of Samsung’s biosimilar drugs in Korea, replacing the role of MSD Korea.The two companies have signed an agreement under which Yuhan will exclusively market and sell Samsung’s biosimilars referencing Enbrel and Remicade in Korea, Yuhan said. Previously, US-based MSD, or Merck & Co., had sold the two Samsung-developed biosimilars, which are marketed locally un